Weeks, Dustin B.

Subject:

From: PRPS SYSTEM NOTIFICATION [PRPS_Trial@uspto.gov]

Sent: Thursday, January 21, 2016 2:25 AM

To: jblake@merchantgould.com; mfedowitz@merchantgould.com; Ettinger, Heather; Robinson,

Joseph R.; Weeks, Dustin B.; Ettinger, Heather Party filing notice received - IPR2015-00990

Attachments: webwbUSPTOSeal2.gif



UNITED STATES PATENT AND TRADEMARK OFFICE PATENT TRIAL AND APPEAL BOARD

Filing Courtesy Notice

Please note the following filing:

Case Number: IPR2015-00990

Filer: NPS Pharmaceuticals, Inc. of Bedminster, NJ

Filing Date: 1/21/2016

Document List

Paper Name	Type	Paper / Exhibit Number			
Transcript of Video					
Deposition of	Exhibit	2042			
Anthony Palmieri	Lamon	2072			
III, Ph.D.					
CV of John F.	Exhibit	2043			
Carpenter, Ph.D.	EXIIIOIL	2043			
CV of Gordon	Exhibit	2044			
Rausser, Ph.D.	Lamon	2044			
Jackson 2012	Exhibit	2045	NPS Ex. 2159		
Onoue 2004	Exhibit	2046	CFAD v. NPS		
	-	^^	IPR2015-01093		



24, 774-77 (1999)		
Joshi 2012	Exhibit	2048
Fang 2012	Exhibit	2049
Blundell 1983	Exhibit	2050
Boesch 1978	Exhibit	2051
Akers 2002	Exhibit	2052
U.S. Pharmacopeia		
788 (2011)	Exhibit	2053
Remington 1990	Exhibit	2054
U.S. Patent		
Publication No.	Exhibit	2055
2013/0310314		
Annex1 Summary	T-1.11.14	2057
of Product Characteristics	Exhibit	2057
Orange Book Listing for Gattex	Exhibit	2058
Eli Lilly and Co.		
(2012)	Exhibit	2059
Al-Hussein 2013	Exhibit	2060
Izutsu 2009	Exhibit	2061
U.S. Pharmacopeia 23, 1650-51 (1995)	Exhibit	2062
Center for Drug		
Evaluation and		
Research,	T	20.52
Application Number	Exhibit	2063
203441Orig1s000,		
Chemistry Review(s)		
U.S. Food and Drug		
Administration,		
FDA Approved	Exhibit	2064
Drug Products -		
Zorbtive.		
Shire, Shire		
completes		
acquisition of NPS	Exhibit	2065
Pharma, February		
21, 2015	T	20.55
Engellenner 2015	Exhibit	2066
Walker, Joseph and		
Rob Copeland, New		
Hedge Fund Strategy Dispute the		
Strategy Dispute the Patent, Short the	Exhibit	2067
Stock, Wall Street		
Journal April 7,		
-		



Wieczner 2015	Exhibit	2068
Buchman 2006	Exhibit	2069
Pirona 2015	Exhibit	2070
O'Keefe 2006	Exhibit	2071
Buchman 1997	Exhibit	2072
NPS 2012 -		
Developing orphan	Exhibit	2073
products for patients		
	Exhibit	2074
O'Keefe 2015 -		
Nutritional Issues in	Exhibit	2076
the SBS	. —	
Tee 2011 -		
Emerging		
Treatment Options	Exhibit	2077
for SBS - Potential		
Role of Teduglutide		
Naberhuis 2015 -		
Teduglutide for	E 1315	2070
Safe Reduction of	Exhibit	2078
Parenteral Nutrient		
Buchman 2012 -		
Teduglutide and	Exhibit	2079
SBS		
FDA - Approved		
Drug Products	Exhibit	2080
Zorbtive		
Crohn's and Colitis		
2013 - Short Bowel	Exhibit	2081
Syndrome and	EXIIIOIL	2081
Crohn's Disease		
Donohoe 2010 -		
Short Bowel	Exhibit	2082
Syndrome		
Zorbtive label	Exhibit	2083
Wales 2010 -		
Human growth	Exhibit	2084
hormone and	LAHIOI	2004
glutamine		
Serono 2005 -	Exhibit	2085
Annual Report	LAMOR	2003
Part 1 Merck 2013 -	Exhibit	2086
Annual Report	EXIIIOII	2080
Part 2 Merck 2013 -	Exhibit	2006
Annual Report	LAIIIUIt	2086
Keller 2004 -		
Management of the	Exhibit	2087
Short Bowel	LAIIIUIt	2007
Crindrama after		



T		
Extensive Small Bowel Resection		
Gattex label	Exhibit	2000
	EXIIIOII	2088
Oley Foundation		
1994 - North	Exhibit	2089
American Home		
Parenteral		
NPS 2011 - NPS		
Pharmaceuticals		
Announces Completion of	Exhibit	2090
Completion of Treatment Phase in		
STEPS		
Seeking Alpha - CEO Discusses Q1	Exhibit	2091
2013 Results	Exilibit	2091
Amiot 2013 -		
Determinants of		
home parenteral	Exhibit	2092
nutrition	Lamon	2072
dependence		
McKeage 2015 -		
Teduglutide - A		
Guide to its Use in	Exhibit	2093
SBS		
FDA 2015 - Orange		
Book Approved		
Drug Products with		•
Therapeutic	Exhibit	2094
Equivalence		
Evaluations		
Jeppesen 2014 -		
Spectrum of short		
bowel syndrome in	Exhibit	2005
adults - Intestinal	EXIIIOIL	2095
insufficiency to		
intestinal failure		
AGA 2003 -		
Technical Review		
on Short Bowl	Exhibit	2096
Syndrome and	Lamon	2070
Intestinal		
Transplantation		
Jeppesen 1999 -		
Quality of life in		
patients receiving	Exhibit	2097
home parenteral		
nutrition		
Jeppesen 2011 -	Exhibit	2098



placebo-controlled		
trial of teduglutide		
in		
ADA 2013 -		
Economic Cost of	Exhibit	2099
Diabetes in the US		
in 2012		
Rodrigues 2011 -		
Short Bowel	Exhibit	2100
Syndrome		
Thompson 2012 -		
Current	Exhibit	2101
Management of	LAmon	2101
SBS		
Jeppesen 2012 -		
Teduglutide		
Reduces Need for	Exhibit	2102
Parenteral Support	Lamon	2102
Among Patients		
with SBS		
Seeking Alpha -		
CEO Discusses Q2	Exhibit	2103
2013 Results		
Seeking Alpha -		
CEO Discusses Q3	Exhibit	2104
2013 Results		
Seeking Alpha -		
CEO Discusses Q4	Exhibit	2105
2013 Results		
Shire 2015 - Q3	E 1314	2106
2015 Results	Exhibit	2106
Shire 2015 - Q3		2 1 0 -
2015 Results	Exhibit	2107
Wolters Kluwer		
Price Data	Exhibit	2108
NPS		
Pharmaceuticals'		
(NPSP) CEO		
François Nader on	Exhibit	2109
Q1 2014 Results -	Zimon	210)
Earnings Call		
Transcript		
Seeking Alpha -		
CEO François		
Nader on Q2 2014	Exhibit	2110
Results		
Seeking Alpha -		
CEO François	Exhibit	2111
Nader on Q3 2014	LAMOIL	4111
1144C1 011 QJ 2014		



DOCKET A L A R M

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

